Yüklüyor......
Global access of rifabutin for the treatment of tuberculosis – why should we prioritize this?
INTRODUCTION: Rifabutin, a rifamycin of equivalent potency to rifampicin, has several advantages in its pharmacokinetic and toxicity profile, particularly in HIV co‐infected patients on combined antiretroviral therapy (cART). In this commentary, we evaluate evidence supporting increased global use o...
Kaydedildi:
| Yayımlandı: | J Int AIDS Soc |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6637439/ https://ncbi.nlm.nih.gov/pubmed/31318176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jia2.25333 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|